GENOMICS SHARED RESOURCE (Core-298) ABSTRACT Overview: The Genomics Shared Resource (GSR) offers UCCC members high-quality and cost-effective services and technical support for high-throughput genomic and proteomic investigation to study cancer pathogenesis, therapeutics, genetic susceptibility and biomarker development. Equipment: The GSR houses equipment to support DNA next-generation sequencing (NGS) (Illumina HiSeq 2000, 2500 and 4000, Illumina MiSeq, and LifeTech IonPGM); DNA microarray analysis (Affymetrix GeneChip and GeneTitan systems; Illumina iScan system; and Agilent SureScan Microarray system); single-cell genomics (Fluidigm C1; Juno; Access Array and Biomark HD Systems); proteomics (Somalogic SOMAscan); and Affymetrix, Agilent and Illumina microarray and sequencing software. Services: The GSR offers methodologies for quantitative assessment of DNA/RNA/Protein including evaluation of human and murine cells harboring shRNA and CRISPR libraries UCCC members have obtained from the Functional Genomics Shared Resource (FGSR). Our capabilities include genome-wide analyses of DNA mutations and RNA expression from tissues to single cells. With these capabilities, the GSR provides: 1) Genome-wide gene variations, gene expression and transcriptome analysis, epigenetics and cytogenomics using NGS and gene microarrays; 2) Single cell genomic analysis; 3) Quantitate selected genes/panels using real time PCR and digital PCR; 4) Proteomic quantitative analysis. Consultation and Education: The GSR provides consultation for designing and analyzing reliable genomics and proteomic experiments and helps keep members up to date as technology advances through seminars and hands-on training. Management: The GSR is an institutional core managed by the UCCC, and is overseen by the Associate Director for Basic Research. Use of Services: Since July 2011, the GSR has provided services to 313 investigators. Forty-seven percent of users (148) were UCCC members, representing all 6 Programs and resulting in 155 peer reviewed publications. CCSG funding represents 5% of the annual operating budget. The remaining support comes from the University of Colorado NIH funded CTSA (Colorado Clinical and Translational Sciences Institute (CCTSI)) grant (4%), and user fees (91%). Future Directions: The GSR has three main future directions that will enhance the SR and UCCC member cancer research: 1) Optimize single cell genomics; 2) Enhance aptamer-based proteomics; 3) Adopt single molecule sequencing.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-29
Application #
9207579
Study Section
Subcommittee A - Cancer Centers (NCI-A)
Project Start
Project End
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
29
Fiscal Year
2017
Total Cost
$132,718
Indirect Cost
$47,369
Name
University of Colorado Denver
Department
Type
Domestic Higher Education
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Harder, Bryan; Tian, Wang; La Clair, James J et al. (2017) Brusatol overcomes chemoresistance through inhibition of protein translation. Mol Carcinog 56:1493-1500
Chen, Yufei; Anastassiadis, Konstantinos; Kranz, Andrea et al. (2017) MLL2, Not MLL1, Plays a Major Role in Sustaining MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell 31:755-770.e6
DeRyckere, Deborah; Lee-Sherick, Alisa B; Huey, Madeline G et al. (2017) UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clin Cancer Res 23:1481-1492
Scarborough, Hannah A; Helfrich, Barbara A; Casás-Selves, Matias et al. (2017) AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition. Clin Cancer Res 23:1531-1541
Neelakantan, Deepika; Zhou, Hengbo; Oliphant, Michael U J et al. (2017) EMT cells increase breast cancer metastasis via paracrine GLI activation in neighbouring tumour cells. Nat Commun 8:15773
Barón, Anna E; Kako, Severine; Feser, William J et al. (2017) Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer. J Thorac Oncol 12:1512-1523
Todd, Maria C; Langan, Thomas A; Sclafani, Robert A (2017) Doxycycline-Regulated p16MTS1 Expression Suppresses the Anchorage-Independence and Tumorigenicity of Breast Cancer Cell Lines that Lack Endogenous p16. J Cancer 8:190-198
Brown, Dustin G; Borresen, Erica C; Brown, Regina J et al. (2017) Heat-stabilised rice bran consumption by colorectal cancer survivors modulates stool metabolite profiles and metabolic networks: a randomised controlled trial. Br J Nutr 117:1244-1256
Haverkos, Bradley M; Abbott, Diana; Hamadani, Mehdi et al. (2017) PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood 130:221-228
Shearn, Colin T; Saba, Laura M; Roede, James R et al. (2017) Differential carbonylation of proteins in end-stage human fatty and nonfatty NASH. Free Radic Biol Med 113:280-290

Showing the most recent 10 out of 1448 publications